These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25812850)

  • 41. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.
    Perrin RJ; Craig-Schapiro R; Malone JP; Shah AR; Gilmore P; Davis AE; Roe CM; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; Kaye JA; Morris JC; Holtzman DM; Townsend RR; Fagan AM
    PLoS One; 2011 Jan; 6(1):e16032. PubMed ID: 21264269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.
    Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Boulanghien J; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Perret-Liaudet A; Touchon J; Lehmann S
    J Alzheimers Dis; 2011; 26(3):553-63. PubMed ID: 21709372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
    Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
    J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endostatin level in cerebrospinal fluid of patients with Alzheimer's disease.
    Salza R; Oudart JB; Ramont L; Maquart FX; Bakchine S; Thoannès H; Ricard-Blum S
    J Alzheimers Dis; 2015; 44(4):1253-61. PubMed ID: 25408220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF biomarker profile and diagnostic value in vascular dementia.
    Paraskevas GP; Kapaki E; Papageorgiou SG; Kalfakis N; Andreadou E; Zalonis I; Vassilopoulos D
    Eur J Neurol; 2009 Feb; 16(2):205-11. PubMed ID: 19146641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
    Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.
    Müller M; Kuiperij HB; Versleijen AA; Chiasserini D; Farotti L; Baschieri F; Parnetti L; Struyfs H; De Roeck N; Luyckx J; Engelborghs S; Claassen JA; Verbeek MM
    J Alzheimers Dis; 2016 Apr; 52(4):1321-33. PubMed ID: 27104900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies.
    Brunnström H; Hansson O; Zetterberg H; Londos E; Englund E
    Int J Geriatr Psychiatry; 2013 Jul; 28(7):738-44. PubMed ID: 22911491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
    Hu Y; He S; Wang J
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
    Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
    J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.
    Parnetti L; Lanari A; Saggese E; Spaccatini C; Gallai V
    Neurol Sci; 2003 Oct; 24(3):199-200. PubMed ID: 14598086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.
    Wennström M; Hall S; Nägga K; Londos E; Minthon L; Hansson O
    Alzheimers Res Ther; 2015 Oct; 7(1):63. PubMed ID: 26434635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
    Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
    Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
    Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
    J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.